Treisman and colleagues tested the effect of MKL1/2 (also referred to as MRTF A/B) shRNA knockdown on global gene expression in invasive breast cancer (MDA-MB-231) and melanoma (B16F2) cell lines [22]. The gene discussed is MRTFA; the disease is melanoma.